Filing Flows › Amneal Pharmaceuticals (AMRX) › Q2 2026 › vs Q1 2026
Amneal Pharmaceuticals (AMRX) Q2 2026 vs Q1 2026 (quarter over quarter)
Amneal Pharmaceuticals's revenue rose $73.7M (+10%) from $723M in Q1 2026 to $796M in Q2 2026. Gross margin 42.0% against 44.3% (-2.3 pts).
Amneal Pharmaceuticals, Q2 2026: revenue $796M (+10% year over year), operating margin 16.3%, net earnings $57.7M, operating cash flow −$21.2M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 42.0% | 44.3% | -2.3 pts |
| Operating margin | 16.3% | 19.6% | -3.3 pts |
| Net margin | 7.2% | 8.6% | -1.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $796M | $723M | $73.7M | +10% |
| Gross profit | $335M | $320M | $14.4M | +4% |
| Cost of revenue | $462M | $402M | $59.3M | +15% |
| Operating profit | $130M | $142M | −$12.0M | -8% |
| Operating expenses | $205M | $178M | $26.4M | +15% |
| Pre-tax earnings | $71.0M | $80.2M | −$9.2M | -11% |
| Other expense, net | $58.8M | $61.6M | −$2.8M | -5% |
| Research & development | $39.0M | $38.4M | $634K | +2% |
| SG&A | $149M | $139M | $9.9M | +7% |
| Other operating costs | $17.0M | $1.1M | $15.9M | 15× |
| Net earnings | $57.7M | $62.3M | −$4.6M | -7% |
| Minority interests | $12.0M | $15.7M | −$3.8M | -24% |
| Income tax | $1.4M | $2.2M | −$800K | -37% |
| Operating cash sources | $89.3M | $97.8M | −$8.5M | -9% |
| Share-based compensation | $10.4M | $8.8M | $1.6M | +18% |
| Cash used in operations | $21.2M | $26.7M | −$5.5M | -21% |
| Working capital & other | $89.3M | $97.8M | −$8.5M | -9% |
Questions
How much did Amneal Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Amneal Pharmaceuticals's revenue rose $73.7M (+10%) from $723M in Q1 2026 to $796M in Q2 2026. Gross margin 42.0% against 44.3% (-2.3 pts).